Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 2/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31417112 | 0.86 | HSD17B10 (0.31) | HSD17B10AHR | |
| SCHEMBL29611270 | 0.82 | GAA (0.33) | HSD17B10TRPA1AHRKDM4EALDH1A1 | |
| SCHEMBL29936022 | 0.79 | RAB9A (0.44) | KDM4EALDH1A1HPGDCYP1A2POLB | |
| SCHEMBL31417275 | 0.79 | GRIN1 (0.39) | HSD17B10SCN5APTGS2PTGS1ALDH1A1 | |
| SCHEMBL24583773 | 0.79 | HSD17B10 (0.36) | HSD17B10SCN5AGABRA1GABRG2GABRB3 | |
| SCHEMBL24583805 | 0.75 | PTGS2 (0.38) | HSD17B10SCN5AGABRA1GABRG2GABRB3 | |
| SCHEMBL31417167 | 0.72 | NT5E (0.34) | HSD17B10SCN5APTGS2TRPA1KDM4E | |
| SCHEMBL16666330 | 0.72 | SCN5A (0.36) | SCN5APTGS2PTGS1KDM4ENPC1 | |
| SCHEMBL17987555 | 0.72 | PIK3CG (0.44) | HSD17B10PTGS2PTGS1AHRKDM4E | |
| SCHEMBL542463 | 0.72 | NPC1 (0.37) | HSD17B10AHRKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217141-A1 | PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 | ENANTA PHARMACEUTICALS, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| US-20250313569-A1 | Pharmaceutical Compounds And Compositions As Modulators Of MAS-Related G-Protein Receptor X2 | ENANTA PHARMACEUTICALS, INC. | 2025-10-09 | — | — | US | disclosed |
| WO-2025044946-A1 | COMPOUND ACTING AS MRGPRX2 ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2025-03-06 | — | — | WO | disclosed |
| CN-119504738-A | Compounds as MRGPRX2 antagonists, methods of preparation and use thereof | 武汉人福创新药物研发中心有限公司 | 2025-02-25 | — | — | CN | disclosed |
| WO-2025011633-A1 | ANTAGONIST OF MAS-RELATED G PROTEIN-COUPLED RECEPTOR X2 AND USE THEREOF | 北京普祺医药科技股份有限公司 | 2025-01-16 | — | — | WO | disclosed |
| EP-2141150-B1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-8110585-B2 | Bicyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-07 | — | — | US | disclosed |
| US-8110585-B2 | Bicyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-07 | — | — | US | disclosed |
| US-8110585-B2 | Bicyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-05-27 | — | — | US | disclosed |
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-05-27 | — | — | US | disclosed |
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-05-27 | — | — | US | disclosed |
| EP-2141150-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-01-06 | — | — | EP | disclosed |
| EP-2141150-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313569-A1 | Pharmaceutical Compounds And Compositions As Modulators Of MAS-Related G-Protein Receptor X2 | MRGPRX2, MRGPRX1, MRGPRX4 | HSD17B10 4766/4885SCN5A 1058/4885GABRA1 491/4885 |
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | MTNR1A, MTNR1B, XDH | HSD17B10 745/4885SCN5A 1876/4885GABRA1 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.